Stockhub

Formycon AG: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

17 August 2022

  • curprev 07:4607:46, 17 August 2022‎ Paris talk contribs‎ 1,175 bytes +1,175‎ Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatmen..." Tag: Visual edit: Switched
Retrieved from ‘https://stockhub.co/research/Formycon_AG’